ALNYLAM PHARMACEUTICALS, INC. Restricted Cash, Current
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Restricted Cash, Current of $1.56 million as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2026-02-12
- 2025-12-31: Restricted Cash, Current $1.56M.
- 2024-12-31: Restricted Cash, Current $2.22M.
- 2023-12-31: Restricted Cash, Current $2.20M.
- 2022-12-31: Restricted Cash, Current $2.16M.
| Period end | Restricted Cash, Current | Restricted Cash, Current as first filed |
|---|---|---|
| 2025-12-31 | $1.56M 10-K · filed 2026-02-12 | |
| 2024-12-31 | $2.22M 10-K · filed 2026-02-12 | |
| 2023-12-31 | $2.20M 10-K · filed 2026-02-12 | |
| 2022-12-31 | $2.16M 10-K · filed 2025-02-13 | |
| 2021-12-31 | $2.18M 10-K · filed 2024-02-15 | |
| 2020-12-31 | $2.47M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $5.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $5.00K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $167.00K 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $2.45M 10-K · filed 2022-02-10 | $4.00K 10-K · filed 2020-02-13 |
| 2019-09-30 | $4.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $332.00K 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $439.00K 10-Q · filed 2020-05-06 | |
| 2018-12-31 | $2.48M 10-K · filed 2021-02-11 | $225.00K 10-K · filed 2019-02-14 |
| 2018-09-30 | $0.00 10-Q · filed 2019-10-31 | |
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |